STOCK TITAN

Glaukos Corporation (GKOS) Stock Price, News & Analysis

GKOS NYSE
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
21 252 sessions, November 17, 2025 to November 17, 2026
Largest daily move
+33.6% close of October 29, 2026
1-year change
+175.2% closing prices, November 17, 2025 to November 17, 2026
1-month change
+47.6% closing prices, October 16, 2026 to November 17, 2026

Company Description

Glaukos Corporation (NYSE: GKOS) is an ophthalmic pharmaceutical and medical technology company that develops and commercializes novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. According to the company’s public disclosures, Glaukos focuses on "dropless" platform technologies and long-duration treatments intended to advance the standard of care for patients living with chronic eye diseases.

Glaukos is incorporated in Delaware and its common stock trades on the New York Stock Exchange under the symbol GKOS. The company reports that it first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. Over time, Glaukos has expanded from micro-scale surgical devices into intracameral implants and pharmaceutical therapies that are designed to deliver drug therapy inside the eye for extended periods.

Core glaucoma therapies and MIGS platform

Glaukos describes three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite. These devices are part of the company’s MIGS platform, which was developed as an alternative to more invasive glaucoma procedures. In addition, Glaukos has commenced commercialization activities for iDose TR, described as a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time.

In its recent communications, the company highlights U.S. and international glaucoma net sales and emphasizes the role of iDose TR in its glaucoma franchise. Glaukos positions iDose TR as a long-duration prostaglandin analog implant that delivers 24/7 glaucoma drug therapy within the eye following intracameral administration.

Corneal health and keratoconus therapies

Beyond glaucoma, Glaukos is active in corneal health. The company reports that it markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. This first-generation corneal cross-linking therapy, known as Photrexa Viscous / Photrexa, received U.S. FDA approval as an orphan drug for the treatment of keratoconus and has been supported by numerous peer-reviewed publications.

Glaukos also announced U.S. FDA approval of Epioxa HD / Epioxa (collectively referred to as Epioxa), which it describes as the first and only FDA-approved, incision-free, topical drug therapy for keratoconus. Epioxa is characterized as an epithelium-on corneal collagen cross-linking therapy that does not require removal of the corneal epithelium. It is described as an oxygen-enriched topical therapeutic that is bioactivated by UV light and is intended to reduce pain associated with conventional procedures, streamline the cross-linking process, and minimize recovery time while delivering clinically meaningful outcomes.

Retinal and broader ophthalmic focus

In its public statements, Glaukos consistently identifies retinal diseases as a third major area of focus alongside glaucoma and corneal disorders. The company describes its overall strategy as developing and commercializing novel ophthalmic therapies and advancing a pipeline of dropless platform technologies aimed at chronic eye diseases. While specific retinal products are not detailed in the provided materials, retinal disease is repeatedly cited as a core therapeutic focus.

Pipeline and dropless platform technologies

Glaukos repeatedly refers to a "robust pipeline of novel, dropless platform technologies" designed to advance the standard of care and improve outcomes for patients with chronic eye diseases. The term "dropless" in the company’s descriptions reflects an emphasis on therapies that can reduce or eliminate the need for frequent topical eye drops by providing long-duration treatment through implants or procedure-based drug delivery.

Examples of this approach include the iDose TR intracameral implant for glaucoma and the Epioxa epithelium-on corneal cross-linking therapy for keratoconus. Both are presented by the company as longer-acting or procedure-based alternatives to conventional, more burdensome treatment regimens.

Manufacturing and U.S. footprint

Glaukos has announced plans to expand its research, development, and manufacturing capabilities through a new facility in Huntsville, Alabama. The company describes this site as a state-of-the-art research, development, and manufacturing facility intended to augment its existing infrastructure, support long-term growth plans, and reinforce its commitment to U.S. manufacturing. The project is characterized as a multi-year investment and is expected to create additional full-time jobs in the region.

Financial reporting and investor communications

Glaukos provides regular financial updates through quarterly and annual results, as reflected in its press releases and Form 8-K filings. These communications highlight net sales, segment performance in glaucoma and corneal health, gross margins, operating expenses, and net income or loss. The company also issues revenue guidance ranges and discusses factors that may affect its performance, such as foreign currency exchange rates and macroeconomic conditions.

In addition, Glaukos makes use of non-GAAP financial measures to supplement its GAAP results, explaining adjustments related to items such as acquisition-related costs, amortization of acquired intangibles, in-process R&D charges, restructuring charges, and other items it identifies for non-GAAP presentation purposes. The company also presents certain net sales information on a constant currency basis to remove the impact of foreign exchange fluctuations.

Regulatory filings and exchange listing

Glaukos files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including Forms 10-Q and 8-K. These filings provide details on financial performance, risk factors, and material events. The company’s common stock is listed on the New York Stock Exchange under the trading symbol GKOS, as reflected in its SEC disclosures.

Position within the medical technology landscape

Within the broader surgical and medical instrument manufacturing sector, Glaukos is distinct in that it combines pharmaceutical therapies with medical technology platforms in ophthalmology. Its business description consistently emphasizes the integration of micro-scale surgical devices, intracameral implants, and bio-activated pharmaceuticals targeting glaucoma, keratoconus, and other chronic eye diseases.

For investors and observers, key aspects of Glaukos’ profile include its role in pioneering MIGS, its portfolio of glaucoma devices and intracameral therapies, its FDA-approved corneal cross-linking treatments for keratoconus, and its stated focus on dropless, long-duration ophthalmic therapies supported by ongoing research and development.

Stock Performance

$243.25
-0.67%
-1.63
Last updated: at
+175.2%
Performance 1 year
$14.4B

Glaukos Corporation (GKOS) closed at $243.25 on November 17, 2026. Over the past 12 months, the price has gained 175.2%.

See what a $1,000 investment in GKOS would be worth today

Average down calculator for GKOS

GKOS Metrics & Rankings

Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Glaukos Corporation has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include conferences, earnings, clinical trial, earnings date, partnership. View all GKOS news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
110,196
Shares Sold
28
Transactions
Most Recent Transaction
Gilliam Joseph E (PRESIDENT & COO) sold 44,917 shares at an average of $246.32 on November 12, 2026

Insider selling at Glaukos Corporation over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Glaukos Corporation generated $507.4M in revenue in FY2025, retaining a 55.7% gross margin, operating income reached -$199.6M (-39.3% operating margin), and net income was -$187.7M, reflecting a -37.0% net profit margin. Diluted earnings per share stood at -$3.28. The company generated -$14.8M in operating cash flow. The current ratio was 4.69, measuring current assets divided by current liabilities.

$507.4M
Revenue (FY2025)
-$187.7M
Net Income (FY2025)
-$14.8M
Operating Cash Flow

Upcoming Events

NOV
18
November 18, 2026 Marketing

Jefferies conference presentation

Management to present at Jefferies conference in London on Nov 18; live and archived webcast on Glaukos investor website.
DEC
01
December 1, 2026 Marketing

Piper Sandler presentation

Management to present at Piper Sandler conference in New York on Dec 1; live and archived webcast on Glaukos investor website.
DEC
02
December 2, 2026 Marketing

Citi conference presentation

Management to present at Citi conference in Miami on Dec 2; live and archived webcast on Glaukos investor website.
YEAR
2027
2027 Marketing

2027 campaign expansion

Expanded 'Could it be KC?' activities planned across 2027, including outreach, community events, educational materials and broader awareness programs.
YEAR
2030
2030 Operations

Facility completion

Completion of new 200,000 sq ft R&D and manufacturing facility in Huntsville, AL

Glaukos Corporation has 5 upcoming scheduled events. The next event, "Jefferies conference presentation", is scheduled for November 18, 2026 (today). Investors can track these dates to stay informed about potential catalysts that may affect the GKOS stock price.

Short Interest History

Last 12 Months

Short interest in Glaukos Corporation (GKOS) currently stands at 4.5 million shares, up 3.2% from the previous reporting period, representing 7.9% of the float. Since November 2025, short interest has increased by 99.3%.

Days to Cover History

Last 12 Months

Days to cover for Glaukos Corporation (GKOS) currently stands at 2.9 days, down 29.5% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 30.1%. Across the settlements charted above, it has ranged from 2.0 to 6.7 days.

GKOS Company Profile & Sector Positioning

Glaukos Corporation (GKOS) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NYSE.

Investors comparing GKOS often look at related companies in the same sector, including Penumbra, Inc. (PEN), Smith & Nephew plc (SNN), Zimmer Biomet Holdings, Inc. (ZBH), Insulet Corporation (PODD), and STERIS plc (STE). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate GKOS's relative position within its industry.

Frequently Asked Questions

The current stock price of Glaukos Corporation (GKOS) is $243.25 as of November 17, 2026.

The market cap of Glaukos Corporation (GKOS) is approximately $14.4B. Learn more about what market capitalization means .

The FY2025 revenue of Glaukos Corporation (GKOS) is $507.4M, from its most recent completed fiscal year.

The FY2025 net income of Glaukos Corporation (GKOS) is -$187.7M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Glaukos Corporation (GKOS) is -$3.28 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Glaukos Corporation (GKOS) is -$14.8M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Glaukos Corporation (GKOS) is -37.0% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Glaukos Corporation (GKOS) is -39.3% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Glaukos Corporation (GKOS) is 55.7% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Glaukos Corporation (GKOS), current assets divided by current liabilities, was 4.69 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Glaukos Corporation (GKOS) is $282.8M for FY2025, its most recent completed fiscal year.

The operating income of Glaukos Corporation (GKOS) is -$199.6M for FY2025, its most recent completed fiscal year. Learn about operating income.

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for glaucoma, corneal disorders, and retinal diseases. Its portfolio includes micro-scale surgical devices, intracameral implants, and bio-activated pharmaceutical therapies designed for chronic eye conditions.

Glaukos reports that it first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. The company’s MIGS platform includes micro-scale surgical devices such as the iStent, iStent inject W, and iStent infinite for the treatment of glaucoma.

According to Glaukos, iDose TR is a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. It is described as a long-duration prostaglandin analog implant that provides 24/7 intraocular pressure-lowering medication after intracameral administration.

Glaukos states that it markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. The company’s first-generation therapy, Photrexa Viscous / Photrexa, received U.S. FDA approval as a corneal cross-linking treatment for keratoconus.

Epioxa HD / Epioxa is described by Glaukos as the first and only FDA-approved, incision-free, topical drug therapy for keratoconus. It is an epithelium-on corneal collagen cross-linking treatment that uses an oxygen-enriched topical therapeutic, bioactivated by UV light, and is intended to avoid removal of the corneal epithelium while providing clinically meaningful outcomes for keratoconus patients.

In its public communications, Glaukos consistently identifies three main therapeutic areas: glaucoma, corneal disorders such as keratoconus, and retinal diseases. The company emphasizes chronic eye diseases and long-duration or dropless treatment approaches within these areas.

Glaukos Corporation’s common stock is listed on the New York Stock Exchange. The trading symbol disclosed in the company’s SEC filings is GKOS.

Glaukos refers to a robust pipeline of novel, dropless platform technologies designed to advance the standard of care and improve outcomes for patients with chronic eye diseases. In the company’s descriptions, dropless approaches include long-duration intracameral implants and procedure-based therapies that aim to reduce reliance on frequent topical eye drops.

Glaukos issues press releases and files Form 8-K reports that discuss net sales, segment performance in glaucoma and corneal health, gross margins, operating expenses, and net income or loss. The company also provides revenue guidance ranges and uses certain non-GAAP financial measures, along with constant currency net sales information, to supplement its GAAP results.

Yes. Glaukos has announced the groundbreaking of a new state-of-the-art research, development, and manufacturing facility in Huntsville, Alabama. The company describes this project as a multi-year investment intended to support its long-term growth plans and reinforce its commitment to U.S. manufacturing.